NLRP3 inflammasome inhibitors are described in a Zomagen Biosciences Ltd. patent and are reported to be useful for the treatment of autoimmune, cardiovascular, inflammatory, liver, lung, metabolic and neurological disorders.

Zomagen Biosciences Ltd. has prepared and tested new NLRP3 inflammasome modulators reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, inflammatory disorders, liver diseases, lung diseases, metabolic diseases and neurological disorders.